• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Dendritic cell vaccines for melanoma: past, present and future.黑色素瘤的树突状细胞疫苗：过去、现在与未来
Melanoma Manag. 2016 Dec;3(4):273-289. doi: 10.2217/mmt-2016-0014. Epub 2016 Nov 29.
2
Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells.用负载α-半乳糖神经酰胺且源自胚胎干细胞的基因工程树突状细胞进行多抗原靶向免疫治疗。
J Immunother. 2009 Apr;32(3):219-31. doi: 10.1097/CJI.0b013e318194b63b.
3
Dendritic cell vaccination in melanoma patients: From promising results to future perspectives.黑色素瘤患者的树突状细胞疫苗接种：从有前景的结果到未来展望。
Hum Vaccin Immunother. 2016 Oct 2;12(10):2523-2528. doi: 10.1080/21645515.2016.1197453. Epub 2016 Jun 20.
4
Dendritic cell vaccines in melanoma: from promise to proof?黑色素瘤中的树突状细胞疫苗：从希望到验证？
Crit Rev Oncol Hematol. 2008 May;66(2):118-34. doi: 10.1016/j.critrevonc.2007.12.007. Epub 2008 Feb 8.
5
Dendritic cell gene therapy.树突状细胞基因治疗。
Surg Oncol Clin N Am. 2002 Jul;11(3):645-60. doi: 10.1016/s1055-3207(02)00027-3.
6
Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.给转移性黑色素瘤患者注射负载同种异体肿瘤裂解物的树突状细胞后抗肿瘤T细胞反应的分析与表征
J Immunother. 2008 Jan;31(1):101-12. doi: 10.1097/CJI.0b013e318159f5ba.
7
Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.mRNA 电穿孔树突状细胞疫苗接种可诱导 III 期和 IV 期黑色素瘤患者产生强烈的肿瘤抗原特异性 CD4+和 CD8+ T 细胞应答。
Clin Cancer Res. 2012 Oct 1;18(19):5460-70. doi: 10.1158/1078-0432.CCR-11-3368. Epub 2012 Aug 15.
8
Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.精准癌症免疫疗法：优化基于树突状细胞的策略以诱导针对个体患者肿瘤的肿瘤抗原特异性T细胞应答。
J Immunother. 2015 May;38(4):155-64. doi: 10.1097/CJI.0000000000000075.
9
Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines.自体树突状细胞负载来自自我更新的自体肿瘤细胞的抗原，作为患者特异性治疗性肿瘤疫苗。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2198467. doi: 10.1080/21645515.2023.2198467. Epub 2023 May 3.
10
Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.携带死肿瘤抗原的天然小鼠常规型 1 树突状细胞的有效癌症免疫疗法。
J Immunother Cancer. 2019 Apr 8;7(1):100. doi: 10.1186/s40425-019-0565-5.

引用本文的文献

1
Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8 T cell and iNKT cell activating mRNA vaccine.纳米抗体介导的 SPECT/CT 成像显示程序性死亡配体 1 对 CD8 T 细胞和 iNKT 细胞激活 mRNA 疫苗的时空表达。
Theranostics. 2023 Oct 9;13(15):5483-5500. doi: 10.7150/thno.85106. eCollection 2023.
2
Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines.自体树突状细胞负载来自自我更新的自体肿瘤细胞的抗原，作为患者特异性治疗性肿瘤疫苗。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2198467. doi: 10.1080/21645515.2023.2198467. Epub 2023 May 3.
3
New Therapeutic Approaches for Conjunctival Melanoma-What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells.结膜黑色素瘤的新治疗方法——目前我们所了解的和潜在的治疗方向：聚焦淋巴管和树突状细胞。
Int J Mol Sci. 2022 Jan 27;23(3):1478. doi: 10.3390/ijms23031478.
4
An update on GM-CSF and its potential role in melanoma management.GM-CSF最新进展及其在黑色素瘤治疗中的潜在作用。
Melanoma Manag. 2020 Jul 29;7(3):MMT49. doi: 10.2217/mmt-2020-0011.
5
Cytokine network analysis of immune responses before and after autologous dendritic cell and tumor cell vaccine immunotherapies in a randomized trial.一项随机试验中自体树突状细胞和肿瘤细胞疫苗免疫治疗前后免疫反应的细胞因子网络分析
J Transl Med. 2020 Apr 21;18(1):176. doi: 10.1186/s12967-020-02328-6.
6
Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment.根据治疗时疾病程度，比较接受患者特异性树突状细胞疫苗治疗的黑色素瘤患者与接受其他免疫疗法的黑色素瘤患者的生存率。
Biomedicines. 2019 Oct 11;7(4):80. doi: 10.3390/biomedicines7040080.
7
Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma.72例转移性黑色素瘤患者使用自体肿瘤抗原的个性化树突状细胞疫苗。
Melanoma Manag. 2019 May 31;6(2):MMT20. doi: 10.2217/mmt-2018-0010.
8
An update on the relevance of vaccine research for the treatment of metastatic melanoma.疫苗研究在转移性黑色素瘤治疗中的相关性最新进展。
Melanoma Manag. 2017 Dec;4(4):203-215. doi: 10.2217/mmt-2017-0021. Epub 2017 Nov 23.
9
Melanoma vaccines and viral-based immunotherapies: a special focus issue from .黑色素瘤疫苗和基于病毒的免疫疗法：来自……的一个特别关注问题
Melanoma Manag. 2016 Dec;3(4):245-246. doi: 10.2217/mmt-2016-0030. Epub 2016 Nov 30.
10
Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses.随机对照 II 期试验自体树突状细胞疫苗与自体肿瘤细胞疫苗治疗转移性黑色素瘤：5 年随访及附加分析。
J Immunother Cancer. 2018 Mar 6;6(1):19. doi: 10.1186/s40425-018-0330-1.

本文引用的文献

1
Is vaccine research still relevant for metastatic melanoma?疫苗研究对转移性黑色素瘤仍有意义吗？
Melanoma Manag. 2014 Nov;1(2):91-94. doi: 10.2217/mmt.14.18. Epub 2014 Dec 4.
2
Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma.自体单核细胞来源的 mRNA 电穿孔树突状细胞（TriMixDC-MEL）联合伊匹单抗治疗预处理晚期黑色素瘤患者的 II 期研究。
J Clin Oncol. 2016 Apr 20;34(12):1330-8. doi: 10.1200/JCO.2015.63.4121. Epub 2016 Feb 29.
3
The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.新抗原在癌症天然发生的和治疗诱导的免疫反应中的作用。
Adv Immunol. 2016;130:25-74. doi: 10.1016/bs.ai.2016.01.001. Epub 2016 Feb 10.
4
Acquisition and Presentation of Tumor Antigens by Dendritic Cells.树突状细胞对肿瘤抗原的获取与呈递
Crit Rev Immunol. 2015;35(5):349-64. doi: 10.1615/critrevimmunol.v35.i5.10.
5
Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T).使用单核细胞衍生树突状细胞的自体黑色素瘤细胞疫苗（NBS20/eltrapuldencel-T）
Future Oncol. 2016 Mar;12(6):751-62. doi: 10.2217/fon.16.13. Epub 2016 Feb 3.
6
Dendritic cell based immunotherapy using tumor stem cells mediates potent antitumor immune responses.基于肿瘤干细胞的树突状细胞免疫治疗介导有效的抗肿瘤免疫应答。
Cancer Lett. 2016 Apr 28;374(1):175-185. doi: 10.1016/j.canlet.2016.01.021. Epub 2016 Jan 20.
7
Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.原发性髓系树突状细胞疫苗接种转移性黑色素瘤患者的有效临床应答。
Clin Cancer Res. 2016 May 1;22(9):2155-66. doi: 10.1158/1078-0432.CCR-15-2205. Epub 2015 Dec 28.
8
Mutation-Derived Tumor Antigens: Novel Targets in Cancer Immunotherapy.突变衍生的肿瘤抗原：癌症免疫治疗中的新靶点。
Oncology (Williston Park). 2015 Dec;29(12):970-2, 974-5.
9
RNA-Based Vaccines in Cancer Immunotherapy.癌症免疫治疗中的RNA疫苗
J Immunol Res. 2015;2015:794528. doi: 10.1155/2015/794528. Epub 2015 Nov 19.
10
Adjuvant Therapy of Melanoma.黑色素瘤的辅助治疗
Cancer Treat Res. 2016;167:181-208. doi: 10.1007/978-3-319-22539-5_7.

黑色素瘤的树突状细胞疫苗：过去、现在与未来

Dendritic cell vaccines for melanoma: past, present and future.

作者信息

Dillman Robert O, Nistor Gabriel I, Cornforth Andrew N

机构信息

AiVita Biomedical, Inc., 18301 Von Karman Avenue, Suite 130, Clinical, Research, and Manufacturing Departments, Irvine, CA 92612, USA.

出版信息

Melanoma Manag. 2016 Dec;3(4):273-289. doi: 10.2217/mmt-2016-0014. Epub 2016 Nov 29.

DOI:10.2217/mmt-2016-0014
PMID:30190899
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6094661/
Abstract

Administering dendritic cells (DC) loaded with tumor-associated antigens (TAA) is a promising strategy for therapeutic vaccines in advanced melanoma. To date the induction of immune responses to specific TAA has been more impressive than clinical benefit because of TAA limitations, suboptimal DC and possibly immune-checkpoint inhibition. Various products, antigen-loading techniques, treatment schedules, routes of administration and adjunctive agents continue to be explored. Biologic heterogeneity suggests autologous tumor as the optimal TAA source to induce immune responses to the entire repertoire of unique patient-specific neoantigens. Many questions remain regarding the optimal preparation of DC and strategies for antigen loading. Effective DC vaccines should result in additive or synergistic effects when combined with checkpoint inhibitors.

摘要

给予负载肿瘤相关抗原（TAA）的树突状细胞（DC）是晚期黑色素瘤治疗性疫苗的一种有前景的策略。迄今为止，由于TAA的局限性、DC不够理想以及可能存在的免疫检查点抑制，针对特定TAA的免疫反应诱导在临床上比实际获益更令人印象深刻。各种产品、抗原负载技术、治疗方案、给药途径和辅助剂仍在不断探索中。生物异质性表明自体肿瘤是诱导针对患者特异性独特新抗原全部组成的免疫反应的最佳TAA来源。关于DC的最佳制备和抗原负载策略仍存在许多问题。有效的DC疫苗与检查点抑制剂联合使用时应产生相加或协同效应。